newsfilter
← Latest News
GlobeNewswire·

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b